Mitochon Pharmaceuticals, Inc.

Mitochon’s small molecule candidate MP101 modulates mitochondrial function to treat neurogenerative diseases. Credit: Solskin via Getty Images. The European Medicines Agency (EMA) has awarded approval to Mitochon Pharmaceuticals to initiate a Phase I/IIa biomarker study to treat patients with several neurogenerative diseases. The 14-day pilot study will investigate MP101, a small molecule orally administered drug which targets mitochondrial function. The clinical trial will enrol patients with amyotrophic lateral sclerosis (ALS), multiple sclerosis, Huntington’s disease, and Alzheimer’s disease, and evaluate the safety and potential changes in disease-specific biomarkers of the drug. Mitochon received orphan drug designation from the US Food and Drug Administration (FDA) for MP101 to treat Huntington’s disease and ALS, in 2019 and 2020, respectively. The candidate generated promising results in preclinical studies, with Mitochon reporting that MP101 indicated favourable pharmacological and biochemical responses. Data showed that MP-101 preserves brain volume, medium spiny neurons, general neurons and limb movement, as well as reducing seizure duration. According to GlobalData’s Pharma Intelligence Center, MP101 has been investigated in several clinical studies, including for optic neuritis, in normal healthy volunteers, and in Huntington’s disease patients. GlobalData is the parent company of Pharmaceutical Technology. In the announcement accompanying the approval, Mitochon’s co-founder and chief scientific officer (CSO) John Geisler said: “We are delighted for the opportunity to explore this provocative idea that most, if not all neurodegenerative diseases are rooted in mitochondrial dysfunction. We predict that chronic treatment with this unique platform, at micro-doses, will resolve mitochondrial issues and change important disease-specific biomarkers in all four indications similarly.” According to GlobalData’s Pharma Intelligence Center, Mitochon has another drug in its pipeline, MP201. The therapy modulates mitochondrial function, protecting the neurons through mitochondrial uncoupling, which prevents excessive ROS formation and oxidative damage. The candidate is also under development for the treatment of Parkinson’s disease, amyotrophic lateral sclerosis, and traumatic brain injury. In July 2023, InSilicoTrials and Axoltis teamed up to develop disease-modifying drugs for neurological disorders. Precision Biosciences filed a patent in September 2023 on a mitochondria-targeting engineered meganuclease for modifying human mitochondrial DNA.

BLUE BELL, Pa.--( BUSINESS WIRE )-- Mitochon Pharmaceuticals today announced that it was awarded approval from EMA to begin enrollment for a Phase I/IIa biomarker study in Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Huntington’s Disease (HD) and Alzheimer’s Disease (AD) participants. Mitochon’s MP101, a once-daily, oral brain penetrant mitochondrial stimulator, that improves central nervous system survival and function will be used in this 14-day pilot study. The aim of the study is to show safety in the target patient populations and demonstrate meaningful changes in disease specific biomarkers. Successful completion of this study will provide the basis for long term Phase IIb clinical studies in ALS, Secondary & Primary Progressive MS, HD, and AD patients, leading to the first mitochondrial specific therapy for these truly insidious diseases. “We are delighted for the opportunity to explore this provocative idea that most, if not all neurodegenerative diseases are rooted in mitochondrial dysfunction. We predict that chronic treatment with this unique platform, at micro-doses, will resolve mitochondrial issues and change important disease specific biomarkers in all four indications similarly,” said Dr. John G. Geisler, Ph.D., co-founder and CSO of Mitochon. MP101 and MP201 are mitochondrial targeted, once-a-day, oral therapies that have been shown to shield cells from damage caused by a host of degenerative processes (genetic and non-genetic, auto-immune and injury). In preclinical studies, these compounds have exhibited striking protective and functional benefits in disease models. Benefits include: brain volume sparing in Huntington’s disease; axonal protection from demyelination in Multiple Sclerosis, protection of neuromuscular junction in ALS, blocking the loss of short-term memory in Alzheimer’s, and protecting brain cells from traumatic brain injury (TBI) such as severe concussions. About Mitochon Pharmaceuticals Mitochon was founded in 2015 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and neuro-trauma. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protection (MOA: https://www.mitochonpharma.com/mechanism-of-action/ ). These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival – similar to the positive effects seen with fasting and exercise. These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition, growth and repair. Additional Information: www.mitochonpharma.com